Maintaining What Is Already There: Strategies to Rectify HSC Transplantation Dilemmas  by Waskow, Claudia
Cell Stem Cell
In TranslationMaintaining What Is Already There: Strategies
to Rectify HSC Transplantation DilemmasClaudia Waskow1,*
1Regeneration in Hematopoiesis and Animal Models in Hematopoiesis, Institute for Immunology, Faculty of Medicine, TU Dresden,
Fetscherstrasse 74, 01307 Dresden, Germany
*Correspondence: claudia.waskow@tu-dresden.de
http://dx.doi.org/10.1016/j.stem.2015.08.012
Hematopoietic stem cell (HSC) transplantation remains the only cure for various hematological diseases, but
low HSC numbers in many donor samples are a critical problem preventing their clinical use. Now in Nature
and Cell, two creative strategies to rescue and improve pre-existing engraftment potential are presented.HSCs are the only adult stem cells that
are routinely used in the clinic for the
replacement of diseased blood tissues
including cell-based therapies and gene
therapeutic approaches. Further, bone
marrow transplantation from healthy indi-
viduals into patients still remains the only
cure for numerous hematological disor-
ders, such as primary immune defi-
ciencies, and also acquired states of
bone marrow failure, including certain
leukemias and anemias. For this reason
HSCs have been studied intensely, and
a better understanding of their biology
and function is required in order to
improve and develop novel, less invasive
therapies in the future. The only available
donor cell sources are cord blood, pri-
mary bone marrow, and mobilized pe-
ripheral blood. The success of a clinical
bone marrow transplantation correlates
with the number of donor HSCs infused
(Danby and Rocha, 2014). Thus, a key
limiting factor for clinically successful
HSC transplantation is often the number
of histocompatible donor HSCs that are
available for a specific patient from those
sources (Li and Sykes, 2012). Despite
rapid progress in understanding the
precise phenotype of HSCs that can
contribute to long-term hematopoiesis in
transplantation recipients, the inability to
obtain or generate donor cell numbers
in sufficiently large numbers for robust
repopulation remains a significant chal-
lenge for clinicians. In fact, low numbers
of donor HSCs make the majority of
stored donor samples—mainly cord
blood—unusable (Danby and Rocha,
2014).
Approaches to improve HSC trans-
plantation have traditionally focused
on increasing numbers of donor HSCs.258 Cell Stem Cell 17, September 3, 2015 ª2Instead, two recent publications now
show that HSC transplantation can be
much improved by maintaining pre-
existing stem cell potential (Mantel
et al., 2015) and by increasing homing ef-
ficiencies (Li et al., 2015), providing
previously unrecognized or ‘‘under-inves-
tigated’’ strategies that may lead to the
use of many more donor samples
(Figure 1).
To understand whether current isola-
tion procedures are compatible with
maximal recovery of stem cell potential,
Broxmeyer and colleagues focused on
the preparation of bone marrow cells un-
der hypoxic conditions to mimic the oxy-
gen concentration in situ (Mantel et al.,
2015). Recovery of mouse and human
HSCs under hypoxic conditions led to
increased numbers of phenotypic HSCs
and correspondingly to improved repo-
pulation potential. HSC numbers were
increased because the low oxygen con-
centration protected them from undergo-
ing an extraphysiologic oxygen shock/
stress response (EPHOSS), which leads
to elevated differentiation when HSCs
are harvested in air. Careful dissection of
the involved pathways showed that har-
vest of HSCs in hypoxia prevents the
accumulation of reactive oxygen species
by increasing the activity of mitochondrial
permeability transition pores (MPTP) that
are regulated by cyclophilin D (CypD)
and p53. Consistently, CypD knockout
mice have increased numbers of HSCs
and p53 deficiency prevents air-expo-
sure-induced EPHOSS. EPHOSS can
also be prevented by using cyclosporine
A (CSA), an FDA-approved small-mole-
cule inhibitor that mimics the protective
cell physiological effects of bone marrow
harvest under hypoxic conditions in015 Elsevier Inc.murine and human cells, supporting
the immense translational potential of
the study. Protection of human HSCs
from EPHOSS by CSA may improve
the outcome of clinical bone marrow
transplantation.
Zon and colleagues applied a different
approach to address the same problem
in HSC transplantation by harnessing
the quantitative power of chemical
screens performed in zebrafish (Li et al.,
2015). Using competitive transplantation
of chemically treated, labeled HSCs com-
bined with in vivo imaging, the authors
identified a new lipid mediator important
for HSC specification during develop-
ment and for enhanced HSC engraftment
upon transplantation. During develop-
ment, treatment of the embryo with
11,12-epoxyeicosatrienoic acid (11,12-
EET) results in increased numbers of
HSCsemerging at the regular site of hema-
topoiesis but also ectopically in a non-he-
matopoietic region of the tail, suggesting
that 11,12-EET is a strong inductor of
HSC fate. Gene expression, knockdown
studies, anda chemical suppressor screen
in zebrafish embryos showed that
increased HSC specification mediated by
11,12-EET depends on PI(3)K-mediated
induction of runx1 expression via the
transcription factor AP-1. In adult mice,
11,12-EET treatment of purified HSCs
also results in increased engraftment,
largely owing to an advantage dur-
ing homing. Finally, bridging the study to
potential clinical use, the authors show
that human cord blood cells upregulate
the expression of AP-1 family members
after brief exposure to 11,12-EET in vitro,
evidencing that this eicosanoid pathway
for hematopoiesis is conserved between
zebrafish, mice, and humans.
Figure 1. Strategies to Improve the Outcome of Bone Marrow
Transplantation by Enhancing HSC Function
Low donor HSC numbers strictly correlate with a poor success rate in bone
marrow transplantation. Current methods to increase donor HSCs by de
novo generation from pluripotent cells (A) or by in vitro expansion (B) have
not proven sufficiently successful to be a viable clinical option yet. Mantel
et al. (2015) rescue pre-existing stem cell potential by using CSA that protects
HSCs from EPHOSS that is induced by exposure to air (C). Li et al. (2015) pre-
sent improvements at the other end—the homing of donor HSCs to bone
marrow niches that provides a significant advantage for the engraftment effi-
ciency in the long-term (D).
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uncover innovative strategies
to improve the outcome
of HSC transplantation and
explore in great detail the
involved pathways to identify
compounds that can be used
for clinical transplantation
in the future. Recent ap-
proaches to improve trans-
plantation outcomes have
focused mainly on in vitro
expansion and the generation
of HSCs from pluripotent
cells. Both scenarios harbor
tremendous potential but
are to date not advanced
enough to be used in experi-
mental or clinical settings
(Danby and Rocha, 2014; Vo
and Daley, 2015). Instead,
Mantel et al. (2015) show that
CSA treatment preserves
HSC function that is already
present but frequently lostdue to the isolation procedure and
may result in novel approaches to obtain
donor samples for clinical HSC transplan-
tation. Similarly, Li et al. (2015) uncover an
eicosanoid pathway that improves the
natural homing capacity of HSCs. It will
be interesting to find out whether this ef-
fect is conserved in human HSCs and
whether this strategy will allow the use of
cord blood samples that have already
been obtained and are currently in stor-age. Such studies in combination with
theuseofmuch improved recipientmouse
strains that allow the engraftment of low
donor HSC numbers in the absence of
inflammation (Cosgun et al., 2014;
Goyama et al., 2015; Waskow et al.,
2009) may present the next step toward
clinical translation. Finally, both studies
exemplarily link basic research on cell bio-
logical functions to clinically highly rele-
vant questions.Cell Stem Cell 17, September 3,ACKNOWLEDGMENTS
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